Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Sold by US Bancorp DE

US Bancorp DE lessened its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 48.7% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 7,368 shares of the company’s stock after selling 6,986 shares during the quarter. US Bancorp DE’s holdings in Amphastar Pharmaceuticals were worth $358,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. TD Asset Management Inc boosted its stake in shares of Amphastar Pharmaceuticals by 67.4% during the second quarter. TD Asset Management Inc now owns 1,691,569 shares of the company’s stock valued at $67,663,000 after acquiring an additional 680,976 shares during the last quarter. Epoch Investment Partners Inc. lifted its holdings in Amphastar Pharmaceuticals by 35.1% in the 2nd quarter. Epoch Investment Partners Inc. now owns 1,078,852 shares of the company’s stock valued at $43,154,000 after purchasing an additional 280,390 shares in the last quarter. American Century Companies Inc. boosted its stake in shares of Amphastar Pharmaceuticals by 19.7% during the 2nd quarter. American Century Companies Inc. now owns 740,408 shares of the company’s stock worth $29,616,000 after purchasing an additional 121,764 shares during the last quarter. Millennium Management LLC raised its position in shares of Amphastar Pharmaceuticals by 84.6% in the second quarter. Millennium Management LLC now owns 738,748 shares of the company’s stock valued at $29,550,000 after buying an additional 338,653 shares during the last quarter. Finally, Boston Trust Walden Corp acquired a new position in shares of Amphastar Pharmaceuticals in the third quarter valued at approximately $26,189,000. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

AMPH has been the subject of several recent analyst reports. Piper Sandler lowered their target price on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $63.00.

Amphastar Pharmaceuticals Stock Down 1.8 %

Shares of AMPH opened at $47.71 on Wednesday. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $36.56 and a fifty-two week high of $65.92. The company’s fifty day moving average is $48.45 and its two-hundred day moving average is $44.34. The firm has a market cap of $2.32 billion, a PE ratio of 15.90, a price-to-earnings-growth ratio of 0.93 and a beta of 0.82. The company has a quick ratio of 2.63, a current ratio of 3.43 and a debt-to-equity ratio of 0.82.

Insider Activity at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 3,000 shares of the company’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $46.47, for a total transaction of $139,410.00. Following the completion of the sale, the director now directly owns 75,409 shares in the company, valued at $3,504,256.23. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Amphastar Pharmaceuticals news, EVP Yakob Liawatidewi sold 5,214 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total value of $271,388.70. Following the transaction, the executive vice president now directly owns 74,938 shares of the company’s stock, valued at $3,900,522.90. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Floyd F. Petersen sold 3,000 shares of the company’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $46.47, for a total value of $139,410.00. Following the completion of the sale, the director now directly owns 75,409 shares of the company’s stock, valued at $3,504,256.23. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 19,640 shares of company stock worth $990,722. 27.10% of the stock is owned by insiders.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.